BridgeBio Pharma (BBIO) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viatris (VTRS) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 87.7% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with +54.0% for VTRS. Viatris is the larger company by market cap ($22.50 billion vs $14.81 billion), about 1.5 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs -3.0%).
Viatris pays a dividend yielding 2.45%, while BridgeBio Pharma does not currently pay one. Viatris converts more of its revenue into profit, with a net margin of -24.6% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | VTRS |
|---|---|---|
| Share price | $76.03 | $19.63 |
| Market cap | $14.81B | $22.50B |
| 1-day change | -2.75% | -1.26% |
| YTD return | -0.60% | +57.67% |
| 1-year return | +11.63% | +87.67% |
| 5-year return | +92.24% | +53.96% |
| Forward P/E | — | 6.94 |
| EPS (TTM) | $-3.03 | $-0.53 |
| Dividend yield | 0.00% | 2.45% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $502.08M | $14.30B |
| Revenue growth (YoY) | +126.26% | -2.98% |
| Net income (latest FY) | $-732.94M | $-3.51B |
| Gross margin | 95.82% | 35.06% |
| Operating margin | -104.25% | -18.62% |
| Net margin | -145.98% | -24.58% |
| 52-week high | $93.42 | $21.20 |
| 52-week low | $62.50 | $10.39 |
| Distance from 52-week high | -18.61% | -7.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +40.73% | +10.04% |
| Average volume | 2.67M | 9.11M |
| Shares outstanding | 194.80M | 1.15B |
| Employees | 1,081 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed BBIO by 76.0 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.45% vs 0.00%).
- Viatris is more profitable, keeping -24.6 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs -2.98%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
BBIO vs VTRS FAQ
Which is bigger, BridgeBio Pharma or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $22.50B compared with $14.81B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, BBIO or VTRS?
VTRS returned +87.67% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BridgeBio Pharma or Viatris?
Viatris pays a dividend yielding 2.45%, while BridgeBio Pharma does not currently pay a regular dividend.
Are BridgeBio Pharma and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.